Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer
{{output}}
Targeted therapies are effective in non-small cell lung cancer (NSCLC) patients with driver gene mutations. Chemotherapy combined with immunotherapy is also a common treatment strategy in lung cancer. However, in previous studies, patients with ALK (Anaplastic... ...
